Quality control of cell-based high-throughput drug screening
| Autor: | Ni Guan, Dale E. Mais, Ming-Wei Wang, Ting Li, Zhiyun Zhang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Drug
Computer science business.industry Drug discovery media_common.quotation_subject High-throughput screening lcsh:RM1-950 Compound management Quality control Nanotechnology Lead (geology) lcsh:Therapeutics. Pharmacology Drug development Cell-based assay Quality (business) Biochemical engineering General Pharmacology Toxicology and Pharmaceutics business media_common Pharmaceutical industry |
| Zdroj: | Acta Pharmaceutica Sinica B, Vol 2, Iss 5, Pp 429-438 (2012) |
| ISSN: | 2211-3843 2211-3835 |
| Popis: | The pharmaceutical industry is presently suffering difficult times due to low productivity of new molecular entities. As a major source of drug leads, high-throughput screening (HTS) has been often criticized for its ‘dead end’ lead compounds. However, the fruitful achievements resulting from HTS technology indicate that it remains a feasible way for drug innovation. Because of increasing considerations of earlier stage ADMET (absorption, distribution, metabolism, excretion and toxicity) in drug development, cell-based HTS is highly recommended in modern drug discovery for its ability to detect more biologically relevant characteristics of compounds in living systems. This review provides a systematic and practical description of vital points for conducting high quality cell-based HTS, from assay development to optimization, compound management, data analyses, hit validation as well as lead identification. Potential problems and solutions are also covered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|